Illumina president and CEO Francis deSouza (Photo by Kevin Dietsch/Getty Images)
July 14, 2021 10:18 AM EDTUpdated July 16, 03:42 AM
Deals
FDA+

EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

Kyle Blankenship

The pro­posed $8 bil­lion merg­er be­tween liq­uid biop­sy firm Grail and can­cer blood screen­ing gi­ant Il­lu­mi­na has met with noth­ing but flack since it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times